---
schema_version: "secwatch.filing_event.v1"
accession: "0001145197-23-000004"
form_type: "8-K"
ticker: "PODD"
cik: "0001145197"
company_name: "INSULET CORP"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:11:59.049187+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Insulet acquires ~400 patents from Bigfoot Biomedical for $25M, licenses others

## Summary
- Acquired ~400 patents and a significant number of patent applications from Bigfoot; $25M one-time fee.
- Insulet gets exclusive, sublicensable license to Step-In Patents in pump-based drug delivery (Insulet Field).
- Bigfoot retains exclusive license to same patents for injector-based drug delivery (Bigfoot Field).
- Non-Step-In Patents are licensed non-exclusively to Insulet in Insulet Field.
- Insulet may take possession of Bigfoot's molds and tooling for Insulet Field within one year.

## SEC filing metadata
- accession: 0001145197-23-000004
- form_type: 8-K
- ticker: PODD
- cik: 0001145197
- company_name: INSULET CORP
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000004/0001145197-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000004/podd-20230209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001145197-23-000004
- JSON: https://secwatch.observer/filing/0001145197-23-000004.json
- Plain text: https://secwatch.observer/filing/0001145197-23-000004.txt

## Key facts
- Material Agreements
  INSULET CORP entered into Patent Assignment and License Agreement with Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (collectively, "Bigfoot") (effective 2023-02-09).
  - Action: entry
  - Agreement: license
  - Counterparty: Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (collectively, "Bigfoot")
  - Effective: 2023-02-09
  source text: On February 9, 2023, Insulet Corporation (the “Company”) entered into a Patent Assignment and License Agreement with Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (collectively, “Bigfoot”) pursuant to which the Company acquired from Bigfoot approximately 400 patents as well as a significant number of patent applications, and licensed a significant number of additional patents and patent applications on a fully paid-up exclusive or non-exclusive basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000004/0001145197-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.